Is Oric Pharmaceuticals, Inc. (ORIC) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.2% / 30% | 18.3% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.2% / 33% | 18.3% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 0.8% / 33% | 68.8% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.2% / 33% | 18.3% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 0.8% / 33% | 68.8% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -41.3% | |
| Return on Assets (ROA) | -26.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$111M |
| Free Cash Flow | -$112M |
| Total Debt | $3M |
| Debt-to-Equity | 1.9 |
| Current Ratio | 14.1 |
| Total Assets | $409M |
Price & Trading
| Last Close | $12.38 |
| 50-Day MA | $11.73 |
| 200-Day MA | $11.02 |
| Avg Volume | 1.6M |
| Beta | 1.4 |
|
52-Week Range
$3.90
| |
About Oric Pharmaceuticals, Inc. (ORIC)
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Oric Pharmaceuticals, Inc. (ORIC) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Oric Pharmaceuticals, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Oric Pharmaceuticals, Inc.'s debt ratio?
Oric Pharmaceuticals, Inc.'s debt ratio is 0.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.8%.
What are Oric Pharmaceuticals, Inc.'s key financial metrics?
Oric Pharmaceuticals, Inc. has a market capitalization of $1.4B. Return on equity stands at -41.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.